Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...
Get Instant Summarized Text (Gist) The FDA has approved Enhertu for treating adults with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow breast cancer. This approval follows the ...
The Food and Drug Administration (FDA) has approved Enhertu ® (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...
Enhertu was developed by AstraZeneca and Daiichi Sankyo and was first approved in December 2019. The effectiveness of the drug was evaluated in a clinical trial involving 866 people with ...
Enhertu reduced the risk of disease progression ... Revenue in the company’s financial statements. Recently, the FDA approved AstraZeneca’s Datroway (datopotamab deruxtecan or Dato-DXd ...
The approval emphasizes the importance of HER2 status testing in metastatic breast cancer to identify eligible patients for Enhertu treatment. The antibody drug conjugate was approved for patients ...
In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA) has ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA ...
Trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) is a HER2-directed antibody-drug conjugate. The agent is approved in the United States for several indications, including treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results